CD8+ T cells are major drivers of the anti-cancer immune response, utilizing granzymes and perforins to kill the target cancer cells, while CD4+ T cells contribute to the anti-cancer immune response through CD8+ T cell priming and the activation of innate immune cells [31,49]. This evidence concerns the gene PRF1 and cancer.